SCHEMBL321723

SCHEMBL321723

CCOCCOc1ccc(O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.60
NR5A1 Q13285 1/20 0.60
APP P05067 2/20 0.54
THRA P10827 1/20 0.51
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
ADRB3 P13945 1/20 0.48
ESR1 P03372 2/20 0.47
CYP19A1 P11511 2/20 0.47
ESR2 Q92731 2/20 0.47
NCF1 P14598 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP3A5 P20815 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA7 P36544 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10694518 0.98 LTA4H (0.58) LTA4HNR5A1APPTHRAADRB2
SCHEMBL10690024 0.93 LTA4H (0.53) LTA4HNR5A1APPTHRAADRB2
SCHEMBL4061378 0.89 NQO1 (0.57) LTA4HTHRANCF1CYP1A2CYP3A4
SCHEMBL16561442 0.88 THRA (0.57) LTA4HNR5A1APPTHRAADRB2
SCHEMBL16561490 0.88 THRA (0.57) LTA4HNR5A1THRAADRB2ADRB1
SCHEMBL10704555 0.87 LTA4H (0.76) LTA4HNR5A1APPESR1CYP19A1
SCHEMBL9150174 0.87 KDM4E (0.56) APPTHRANCF1CYP1A2CYP3A4
SCHEMBL2471330 0.87 APP (0.67) LTA4HNR5A1APPESR1ESR2
SCHEMBL19284359 0.87 APP (0.67) LTA4HNR5A1APPESR1ESR2
SCHEMBL6860317 0.87 APP (0.67) LTA4HNR5A1APPESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0748307-A1 SKIN LIGHTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-12-18 EP claimed
WO-1995023780-A2 SKIN LIGHTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1995-09-08 WO claimed
CN-110387035-B Demulsifier, preparation method thereof and application thereof in demulsification of thick oil containing asphaltene 中国石油化工股份有限公司 2022-01-04 CN disclosed
CN-110387035-A Demulsifier and preparation method thereof and the application in asphaltenes thick oil emulsion breaking 中国石油化工股份有限公司 2019-10-29 CN disclosed
EP-1856198-B1 WATER ACTIVATED OXYGEN SCAVENGING COMPOSITION MULTISORB TECH INC (US) 2014-11-19 EP disclosed
US-20130261178-A1 PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES MISTRY SHAILESH (GB) 2013-10-03 US disclosed
EP-2590937-A1 PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES The University Of Nottingham (GB) 2013-05-15 EP disclosed
US-8277892-B2 Process for creating an oxygen scavenging particle MULTISORB TECHNOLOGIES, INC. (US) 2012-10-02 US disclosed
WO-2012004549-A1 PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES THE UNIVERSITY OF NOTTINGHAM (GB) 2012-01-12 WO disclosed
EP-1797213-B8 METHOD OF MAKING VAPOUR DEPOSITED OXYGEN-SCAVENGING PARTICLES MULTISORB TECH INC (US) 2011-10-12 EP disclosed
EP-1797213-B1 METHOD OF MAKING VAPOUR DEPOSITED OXYGEN-SCAVENGING PARTICLES M & G POLIMERI ITALIA SPA (IT) 2011-07-27 EP disclosed
US-20030100616-A1 3-AMINO-PROPOXYPHENYL DERIVATIVES (I) LOUIS, WILLIAM JOHN, AUSTIN AND REPATRIATION MEDICAL CENTRE (AU) 2003-05-29 US disclosed
EP-0937030-A4 3-AMINO-PROPOXYPHENYL DERIVATIVES (I) UNIV MELBOURNE (AU) 2000-06-07 EP disclosed
EP-0937030-A1 3-AMINO-PROPOXYPHENYL DERIVATIVES (I) THE UNIVERSITY OF MELBOURNE (AU) 1999-08-25 EP disclosed
WO-1997013744-A1 3-AMINO-PROPOXYPHENYL DERIVATIVES (I) THE UNIVERSITY OF MELBOURNE (AU) 1997-04-17 WO disclosed
EP-0748307-A1 SKIN LIGHTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-12-18 EP disclosed
WO-1995023780-A2 SKIN LIGHTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1995-09-08 WO disclosed
US-4734471-A Method of curing polyfluoroalkoxyphosphazene ETHYL CORPORATION (US) 1988-03-29 US disclosed
US-4088764-A CARDIOVASCULAR DISORDERS, BETA-ADRENERGIC BLOCKING AGENTS, ANTIARRHYTHMIC AGENTS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1978-05-09 US disclosed
US-4066768-A ADRENERGIC BLOCKING AGENTS, ANTIARRHYTHMIC CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1978-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261178-A1 PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES NR3C2, NPR3, ADRB3 LTA4H 2032/4885NR5A1 98/4885APP 1892/4885
US-20030100616-A1 3-AMINO-PROPOXYPHENYL DERIVATIVES (I) ADRB1, ADRB3, ADRB2 LTA4H 2013/4885NR5A1 632/4885APP 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.